Abstract: A crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, with a large particle size, which belongs to a triclinic crystal system and space group P-1. A crystallization method for making the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, comprising adding a solid of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide to a solvent and mixing; followed by heating to 50 to 70° C. to achieve complete dissolution; cooling the solution to room temperature; and adding an anti-solvent to the resulting solution to cause precipitation of crystals. The crystals are allowed to grow at a constant temperature for 10 to 60 minutes, so as to give a slurry containing the crystals. Said slurry is subjected to filtration and then drying to obtain the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide.

Abstract: The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value ?* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value ?* ranging from 92 to 100. Solvents with a polarity value ?* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility.

Abstract: The disclosure relates to etoricoxib solvates and a preparation method thereof. A solvent is a hydrogen bond donor solvent with a polarity value ?* ranging from 60 to 100 or a hydrogen bond acceptor solvent with a polarity value ?* ranging from 92 to 100. Solvents with a polarity value ?* within the above range all can form corresponding etoricoxib solvates with etoricoxib. The etoricoxib solvate can be prepared by cooling crystallization or suspension crystallization. A 1,2-propanediol solvate of etoricoxib and a dimethyl sulfoxide (DMSO) solvate of etoricoxib provided in the present disclosure have high thermal stability, unique crystal form, large size, concentrated distribution, and prominent flowability and is safe, pharmaceutically acceptable, and not easy to agglomerate. Compared with etoricoxib, the etoricoxib solvates exhibit significantly improved solubility.

Abstract: A crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, with a large particle size, which belongs to a triclinic crystal system and space group P-1. A crystallization method for making the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide, comprising adding a solid of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide to a solvent and mixing; followed by heating to 50 to 70° C. to achieve complete dissolution; cooling the solution to room temperature; and adding an anti-solvent to the resulting solution to cause precipitation of crystals. The crystals are allowed to grow at a constant temperature for 10 to 60 minutes, so as to give a slurry containing the crystals. Said slurry is subjected to filtration and then drying to obtain the crystalline form of phenyl bis (2,4,6-trimethylbenzoyl) phosphine oxide.

Abstract: In some embodiments, a method may calculates a latest seekable point for a live edge of a media program and determines a current playback position of the media program. The latest seekable point for the live edge corresponds to a latest time in the media program that can be played within a threshold. The method selects among a first range, a second range, and a third range based on the current playback position and the latest seekable point. A first feature is enabled when the first range is selected, a second feature is enabled when the second range is selected, and whichever of the first feature or the second feature that is currently enabled is not changed to continue displaying whichever of the first feature and the second feature that is currently enabled when the third range is selected.

Abstract: In some embodiments, a method may calculates a latest seekable point for a live edge of a media program and determines a current playback position of the media program. The latest seekable point for the live edge corresponds to a latest time in the media program that can be played within a threshold. The method selects among a first range, a second range, and a third range based on the current playback position and the latest seekable point. A first feature is enabled when the first range is selected, a second feature is enabled when the second range is selected, and whichever of the first feature or the second feature that is currently enabled is not changed to continue displaying whichever of the first feature and the second feature that is currently enabled when the third range is selected.

Abstract: In some embodiments, a method may receive a seekable range position for the live edge of a live media program and a current playback time. A distance between the position and the current playback time is calculated and compared to three or more feature ranges. A first range is where the user is considered watching live, a second range is where the user is considered not watching live, and a third range is where the user state is not changed. The method enables a first feature that displays a first control indicating that the media program is in a live state for a first range. The method enables a second feature that displays a second control to allow seeking to the live edge for a third range. The method does not change whichever of the first feature or the second feature this is currently enabled for a second range.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: A novel crystalline form is defined by using diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peaks of differential scanning calorimetry (DSC). Pantoprazole Sodium solid is added to an alcohol solvent to form a suspension with a concentration of 0.05˜0.2 g/mL, and then an antioxidant is added to the suspension, completely dissolving the solid at a temperature of 15˜35° C., and a solventing-out agent is dropwise added to the solution under the application of ultrasonic wave, wherein the amount of the solventing-out agent is 3˜10 times (in volume) of the alcohol solvent; followed by cooling the solution down to 0˜5° C., continuing to stir for 1˜3 h, and suction filtrating obtained solid-liquid suspension to provide a novel crystalline form of Pantoprazole Sodium crystal after drying the product to constant weight.

Abstract: A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 30˜45° C. to form a solution, whose concentration is controlled within 0.05˜0.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 3˜5 times (in volume) of that of the solvent; followed by cooling the solution down to 0˜10° C. at a rate of 0.2˜1° C./min; continuing to stir for 1˜3 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

Abstract: A novel crystalline form is defined by diffraction angle 2?° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

Abstract: A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 30˜45° C. to form a solution, whose concentration is controlled within 0.05˜0.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 3˜5 times (in volume) of that of the solvent; followed by cooling the solution down to 0˜10° C. at a rate of 0.2˜1° C./min; continuing to stir for 1˜3 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.